FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Preferred Pharmaceuticals Metformin HCl Extended Release Tablets 500 mg Recall

Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Siz…

Preferred Pharmaceuticals, Inc. · Anaheim, CA

Risk level
Class II
Reported by FDA
Nov 25, 2020
Recall ID
D-0077-2021
Check your lot numberHow we source this data

Summary

Preferred Pharmaceuticals recalled Metformin HCl Extended Release Tablets 500 mg starting Nov 1, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0077-2021 on Nov 25, 2020. Reason: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. Status: Terminated.

Why it was recalled

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Product description

Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc.

Lot numbers, UPCs & expiration codes

E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022

Where it was sold

Distributed to two physician's offices located in FL.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0077-2021
Classification
Class II
Status
Terminated
Recall initiated
Nov 1, 2020
FDA report date
Nov 25, 2020
Quantity
99 bottles (9990 Extended Release Tablets)
Recall type
Voluntary: Firm initiated
Recalling firm
Preferred Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0077-2021, exactly as published.

Show all FDA fields
City
Anaheim
State
CA
Status
Terminated
Country
United States
Event ID
86696
Address
1250 N Lakeview Ave Ste O
Code information
E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022
Postal code
92807-1801
Report date
Nov 25, 2020
Product type
Drugs
Recall number
D-0077-2021
Classification
Class II
Recalling firm
Preferred Pharmaceuticals, Inc.
Product quantity
99 bottles (9990 Extended Release Tablets)
Termination date
May 20, 2024
Reason for recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc.
Distribution pattern
Distributed to two physician's offices located in FL.
Recall initiation date
Nov 1, 2020
Initial firm notification
Letter
Center classification date
Nov 14, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0077-2021, published Nov 25, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls